Overview

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jason Ahee, M.D.
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination